Ocugen Inc (OCGN) concluded trading on Thursday at a closing price of $0.63, with 7.55 million shares of worth about $4.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.88% during that period and on March 06, 2025 the price saw a gain of about 9.96%. Currently the company’s common shares owned by public are about 291.37M shares, out of which, 285.71M shares are available for trading.
Stock saw a price change of 3.34% in past 5 days and over the past one month there was a price change of -15.04%. Year-to-date (YTD), OCGN shares are showing a performance of -21.66% which decreased to -28.34% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.55 but also hit the highest price of $2.11 during that period. The average intraday trading volume for Ocugen Inc shares is 4.65 million. The stock is currently trading -4.46% below its 20-day simple moving average (SMA20), while that difference is down -13.60% for SMA50 and it goes to -43.49% lower than SMA200.
Ocugen Inc (NASDAQ: OCGN) currently have 291.37M outstanding shares and institutions hold larger chunk of about 24.78% of that.
The stock has a current market capitalization of $183.47M and its 3Y-monthly beta is at 3.94. It has posted earnings per share of -$0.18 in the same period. It has Quick Ratio of 2.86 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OCGN, volatility over the week remained 11.49% while standing at 7.62% over the month.
Stock’s fiscal year EPS is expected to drop by -30.00%.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on October 15, 2024 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by Chardan Capital Markets stated Ocugen Inc (OCGN) stock as a Buy in their note to investors on March 01, 2023, suggesting a price target of $3.50 for the stock. On August 23, 2022, Mizuho Initiated their recommendations, while on June 15, 2022, ROTH Capital Resumed their ratings for the stock with a price target of $8. Stock get an Overweight rating from Cantor Fitzgerald on June 02, 2022.
